Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Helen Shih, MD, MS, MPH, FASTRO, medical director, MGH Proton Therapy Centers; director, CNS & Eye Service; and program Director, Proton Therapy Fellowship, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Transcript
What risks have you seen associated with treating or waiting to treat patients with low-grade gliomas?
It's geography, it's the location. So some parts of the brain are relatively safe to treat, other parts of the brain are near radiation-sensitive structures. And if the radiation dose that's needed to treat a tumor is very close to a radiation-sensitive structure, there's a risk of injuring or impairing the function of something else, such as hearing or vision, or it can just lead to symptoms of like—if we’re treating a larger area or near certain areas—you can have a higher risk of nausea, feeling unwell.
Most of those symptoms during the time of radiation are temporary, thankfully, and do resolve. Even things like hair loss, you know, the hair, the scalp, the hair follicles will determine whether or not hair loss during radiation is going to be temporary or permanent, or something in between. So a lot of it depends on location.
I think another consideration is when you see someone with a low-grade glioma at the first diagnosis, that's the smallest the tumor is ever going to be. Some of the treatments may be able to reduce the density of the tumor and kill off tumor cells, so that there is literally less tumor cells, but the footprint of where the tumor extends to tends to be the same, and then over time it will increase, as it tends to spread beyond the initial volume at time of initial diagnosis. So if you wait on giving radiation treatment, sometimes it's a good thing because you're delaying or avoiding side effects associated with radiation.
But on the flip side, it can also grow beyond the initial volume and then you eventually get radiation. You can actually have more side effects if it's now growing toward, for example, the pituitary gland, which it wasn't at initially, and if that later involves collateral radiation of the pituitary gland, that can cause hormonal or endocrine problems that may not have occurred if you treated the patient first diagnosis.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More